Candel Therapeutics (CADL) stock

Cancer immunotherapies , market cap $615M

Viral immunotherapies to fight cancer

Worth $615M

$9.35

-1.48%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#130of 281

Biotech

Checks firing

4of 14

Trending up

From 52-week high

-33.2%

under its best in a year

CADL's Quality Score was unchanged on Tue, Nov 10, at 1.

Follow CADL's trial news. Pro members can get an alert when Candel Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CADL files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…its phase 1b clinical trial of linoserpaturev in patients with recurrent high-grade glioma (rHGG) in Q4 2026…”Trial data · SEC filing · Aug 13

Why CADL rose 16% since Nov 5

Up 16% from Nov 5 to Nov 10.

Candel Therapeutics rose 16% from Nov 5 to Nov 10. 9 points of it came on Nov 9.

Sources: Price history, Nov 10, 2026

1 more reason, free with an account →How the business stands, the timeline, and its peers, for Pro members.

Key facts on CADL

Key facts on CADL
Holding it back	44.0% more shares than a year ago from Massive's market data
Latest filing	10-Q, Aug 13 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind CADL's 1, free with an account →2 more reasons behind CADL's 1, for Pro members.

CADL in the news

ReportExpected to report Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, +0.4% on average. Past reports ›

What's next

Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

CADL catalysts

Coming up

After its last 4 reports it closed +0.4% on average, higher 1 of 4 times.

What's next for CADL, and how long its cash lasts

Next step the company has named

Q4 2026“The Company expects to present potential long-term survival data from arm C of its phase 1b clinical trial of linoserpaturev in patients with recurrent high-grade glioma (rHGG) in Q4 2026.”Trial data · SEC filing · Aug 13

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: LuTK03Phase 3 · Recruiting · 500 people · main data estimated Oct 22, 2031 · NCT07660094

4 more trials, 2 more milestones and 49 filings, for Pro members.

Cash runway

The company says its cash lasts into Q1 2028 (8-K, Aug 13).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Aug 14, 2025)
At-the-market share sales program (S-3, filed Aug 14, 2025)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CEO Paul Peter Tak sold 280,245 shares on Sep 11, under a planned sale. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Paul Tak buys or sells

For Pro members: every trade, and Paul Tak’s 17 filings and quotes.

Get an alert when CADL files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why CADL scores 1

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
−2Dilution 44.0% more shares outstanding than a year ago, from Massive's market dataNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend adds
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Profit, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on CADL and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when CADL's Quality Score turns up

A free account. No card.

How CADL ranks in Biotech

CADL is #130 of 281 by Quality Score.

How CADL ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	BNTXBioNTech		Open for its score
	BRVEBraveheart Bio		Open for its score
	CAPRCapricor Therapeutics		Open for its score
	CGEMCullinan Therapeutics		Open for its score
130	CADLCandel Therapeutics	4/14	1

When does CADL report earnings, and what happens after?

Expected to report Thu Nov 12, before the open (in 2 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CADL reported on Aug 13, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily due to higher clinical trial and manufacturing costs, in support of the Company’s aglatimagene programs, and an increase in employee-related expenses.”

The filing on EDGAR

Where the sales came from

CADL's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase was primarily due to higher commercial readiness costs and an increase in employee-related expenses.”

From its results filing (SEC filing · Aug 13)

1 more sentence, for Pro members.

The numbers

Market value: $615M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CADL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.4%-0.3%+10.5%

Mar 12May 14Aug 13

Reported	When	Gap	Reaction	5 days
Aug 13, 2026Before open	Before open	+1.6%	+10.5%	+26.4%
May 14, 2026Before open	Before open	+2.8%	-0.3%	-13.8%
Mar 12, 2026Before open	Before open	-1.8%	-2.4%	-1.2%

CADL closed higher after 1 of its last 4 reports.

All 4 reports, and CADL's Quality Score going into each

Everyone reporting earnings this week

CADL has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on CADL, and all 14 on every stock.Get in free →

CADL RSI today: 52.5, below its 50-day, above its 200-day

Not scored

RSI 52.5, MACD above signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on CADL

What it does and how it makes money2 findings"Likewise, we own a U.S. patent relating to our CAN-2409 product candidate that expires in 2034, and our in-licensed U.S. and non-U.S. patents relating to our HSV-based product candidates, licensed from MGB and from Periphagen are expected to expire in 2036 and in 2037 …" (10-K for fiscal 2022)SEC filing · Mar 30, 2023
Where it stands3 findings3 offerings of shares or notes since Dec 2024, $160M where the filing states the size.SEC filing · Feb 20, 2026
What changed in its filings5 findings"On January 13, 2023, we filed a demand for arbitration against Periphagen with the American Arbitration Association, seeking a declaration that Periphagen’s December 15 letter failed to comply with the dispute and escalation provisions in the Periphagen License Agreement." (10-K for fiscal 2022)SEC filing · Mar 30, 2023A new heading in its "Risk Factors" this year: "Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties …" (10-K for fiscal 2022; not in fiscal 2021's)SEC filing · Mar 30, 2023, against the one of Mar 29, 2022
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades CADL, for Pro members

7 more findings on CADL, each with its source, for Pro members.

CADL share count over time

44% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of CADL outstanding, as filed
Shares outstanding	As of
76.5M	Aug 6, 2026
73.3M	May 7, 2026
73.2M	Mar 5, 2026
54.9M	Nov 5, 2025

Offerings, shelves, and splits of CADL, from its filings
From its filings	Filed
Raised $100M in a sale of shares, about 16% of its market value	Feb 20, 2026
Registered shares for a later sale (S-3)	Aug 14, 2025
Priced a sale of shares	Jun 24, 2025
Raised $60M in a sale of shares, about 10% of its market value	Dec 13, 2024

CADL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Paul Peter TakChief Executive Officer · 2 trades
Seshu TyagarajanChief Technology Officer · 2 trades
Francesca BaroneChief Scientific Officer · 1 trade
Paul B. ManningDirector · 1 trade

See insider trades by person

Which ETFs hold CADL?

In ETFs: CADL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Candel Therapeutics

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

55 employeesNeedham, MAcandeltx.com

What Candel Therapeutics says it competes with

“The development and commercialization of new product candidates is highly competitive.”

From its annual report, SEC filing · Mar 30, 2023

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on CADL and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn CADL's score around: 8 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

See CADL's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: CADL's Quality Score is 1 (Below Average), #130 of 281 in Biotech.

What does CADL's Quality Score say?

CADL scores 1 today, which Breakaway calls Below Average. It is #130 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 16% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CADL's Quality Score?

CADL scores 1 today, which Breakaway calls Below Average (0 to 5). That is #130 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CADL's 1.

When does CADL report earnings?

Expected to report Thu Nov 12, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. CADL closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.